We would love to hear your thoughts about our site and services, please take our survey here.
Your missing the point. Prior to CF Venn was barely breaking even. Now it's highly profitable.
Let's forget about sentiment and emotion for a moment and stick to facts.
CF has turned two loss-making companies around in the space of less than two years and increased revenues from £3m in 2019 to £20m in 2020 to £50m (estimate) for 2021. Orph is now very profitable month on month, something never achieved before by Venn or Hvivo. The core business alone undervalues the company by a wide margin when you consider typical values of CROs, let alone those in the infectious disease space during a pandemic. The non-core asset values cannot realistically be valued at present but will certainly add substantial value in time to Orph shareholders with three more spin-outs to come. Orph owns the world's largest database of infectious disease progression data. Medical data is hugely valuable and will be sought after by numerous pharma companies as well as the 'wearable' tech giants. The sky really is the limit for DIM alone. Imutex similarly could command a value in the hundreds of millions. CF is close to extracting value from all four spin-outs. But it does clearly take time - something the pessimistic posters fail to acknowledge. CF has always been straight and direct with shareholders and has substantial skin in the game. He may come across as ebullient and ambitious with forecasts at times but personally I'd rather have a CEO like CF than some dried-up old deadwood for a CEO whose heart isn't in it. Everything CF says is achievable in time. Time....it is the essence of success on AIM. Patience for those who are prepared to sit it out with Orph I truly believe will be richly rewarded.
Great news Gerry. We always knew it would come.
Newuncle, it's a difficult one trying to gauge next year's revenues but a good starting point would be the Turner Pope report. In particular look at the sections on microtox PD rollout and cost per unit. Also in the STC rollout section of the article do the same, look at the estimated revenue per month based on projected rollout figures. I would say your revenue projections are very conservative on that basis.
Great article Wally. Thanks very much for posting it.
Cheereo!
The sp will follow the substantial progress of the company eventually. Increasing revenues, news due on multiple fronts including skin trust club, China Resources, microtox PD rollout. Just have to be patient that's all.
Have people woken up and spotted the grammatical error?
Great 18.55 post drshan. You've absolutely nailed it about Chuggin. But I honestly believe that it's best if people just ignore him from now on as people like him thrive on attention.
Terrific summary wally, thanks so much.
Fantastic results. Congratulations Cathal and to your team. So great to have another large contract too.
Great results Gerry. Looks like we're well on track for achieving forecasted revenues for 2021. Another triple digit revenue growth and only at the start of an epic journey.
I don't think AIM is for you Muggins if you have no patience. To suggest DVRG has made no progress is simply ludicrous. I suggest you read the detailed broker note from Turner Pope to appreciate the enormous turn around and progress that GB has achieved. If your not happy then sell up and move on.
'Crushing indictment of the incompetence of this company'.
Give it a rest Muggins. You name me one company which has achieved as much as DVRG in terms of rapid expansion, massive revenue growth and long term potential. What Gerry and the team have achieved in a short space of time is nothing less than extraordinary. All that is needed now is patience. Clearly you don't have any.
Wow...fantastic news. Absolutely huge contract!
Seems like Vitality CBD has been picked up at a good price. £10 million for a fast growing CBD company generating £600,000 EBITDA with improving margins is a bargain. A P/E of 30 would be a reasonable multiple for a profitable fast growing company in the CBD space. Yooma is ticking all the boxes.
The sp and nav gap will close when there's more transparency with regards to the accounts, and that will only happen as the investee companies become listed. Ed is striving to make this happen as quickly as possible but it's not easy and will take time. It's refreshing that we finally have a CEO who is much more engaging with shareholders and prepared to do interviews and updates via twitter. It feels like a real sea change and revelation compared to the previous management.